Cameron L D, Leventhal H, Love R R
Department of Psychology, University of Auckland, New Zealand.
Health Psychol. 1998 Sep;17(5):459-69. doi: 10.1037//0278-6133.17.5.459.
Postmenopausal women with breast cancer in remission (N = 140) who were participating in a randomized clinical trial of tamoxifen chemoprevention therapy completed measures of trait anxiety, symptoms, cancer worry, and breast self-examinations (BSEs) during the first 6 months of the trial. Trait anxiety was associated with heightened sensitivity to tamoxifen-induced symptoms (but not with tendencies to report increases in symptoms unrelated to tamoxifen use), greater tendencies to attribute symptoms to tamoxifen use, and greater cancer worry. Tamoxifen use increased BSE rates among high-anxiety participants. For low-anxiety participants, tamoxifen use increased cancer worry but not BSE rates. Trait anxiety appears to be associated with vigilant activation of illness-related representations that trigger attentiveness to sensations, worry, and protective coping in response to somatic cues.
处于缓解期的绝经后乳腺癌女性（N = 140）参与了一项他莫昔芬化学预防疗法的随机临床试验，在试验的前6个月完成了特质焦虑、症状、癌症担忧和乳房自我检查（BSE）的测量。特质焦虑与对他莫昔芬引起的症状的更高敏感性相关（但与报告与使用他莫昔芬无关的症状增加的倾向无关）、将症状归因于使用他莫昔芬的更大倾向以及更大的癌症担忧。在高焦虑参与者中，使用他莫昔芬会提高BSE率。对于低焦虑参与者，使用他莫昔芬会增加癌症担忧，但不会提高BSE率。特质焦虑似乎与疾病相关表征的警惕性激活有关，这种激活会引发对感觉、担忧和针对躯体线索的保护性应对的关注。
